Smyth2
Bluelighter
- Joined
- Jul 26, 2011
- Messages
- 439
Did a patent search yesterday on SNDRIs and found the following:
[1] George GARIBALDI, WO2023161533 (to Noema Pharma AG).
[2] Jean-Michel Adam, et al. WO2013160273 (to F Hoffmann La Roche AG).
[3] Pravin Iyer, et al. WO2008074703 (to Roche Palo Alto LLC).
[4] Lucas, M. C., Weikert, R. J., Carter, D. S., Cai, H.-Y., Greenhouse, R., Iyer, P. S., Lin, C. J., Lee, E. K., Madera, A. M., Moore, A., Ozboya, K., Schoenfeld, R. C., Steiner, S., Zhai, Y., Lynch, S. M. (September 2010). "Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain". Bioorganic & Medicinal Chemistry Letters. 20 (18): 5559–5566. doi:10.1016/j.bmcl.2010.07.020.
I checked the website
noemapharma.com
It could be that the compound is NOE-115 but it is still too early to say.
On this webpage it says NOE-115 "The therapeutic candidate is a triple reuptake inhibitor targeting, sodium dependent dopamine transporter, sodium dependent noradrenaline transporter and sodium dependent serotonin transporter. It is administered through oral route as a capsule."
[1] George GARIBALDI, WO2023161533 (to Noema Pharma AG).
[2] Jean-Michel Adam, et al. WO2013160273 (to F Hoffmann La Roche AG).
[3] Pravin Iyer, et al. WO2008074703 (to Roche Palo Alto LLC).
[4] Lucas, M. C., Weikert, R. J., Carter, D. S., Cai, H.-Y., Greenhouse, R., Iyer, P. S., Lin, C. J., Lee, E. K., Madera, A. M., Moore, A., Ozboya, K., Schoenfeld, R. C., Steiner, S., Zhai, Y., Lynch, S. M. (September 2010). "Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain". Bioorganic & Medicinal Chemistry Letters. 20 (18): 5559–5566. doi:10.1016/j.bmcl.2010.07.020.
I checked the website
Noema Pharma
OUR PIPELINE A Singular Focus on CNS Mediated Conditions Noema Pharma is committed to developing treatments for debilitating disorders of the central nervou ...
noemapharma.com
On this webpage it says NOE-115 "The therapeutic candidate is a triple reuptake inhibitor targeting, sodium dependent dopamine transporter, sodium dependent noradrenaline transporter and sodium dependent serotonin transporter. It is administered through oral route as a capsule."
Last edited:
